Markets

Microcap biotech Benitec Biopharma revives US IPO with 61% lower deal size and warrants

a generic image of a person pointing at a graph
Credit: Shutterstock photo

Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, reduced the number of ADSs it plans to offer, added warrants and replaced the lead underwriter ahead of its upcoming IPO on Monday. It had been scheduled to price last week but announced its postponement on Thursday. Benitec's stock currently trades on the Australian Securities Exchange under the symbol BLT at a converted price of $13.55 per ADS.

The Balmain, Australia-based company now plans to raise $25 million by offering 1.9 million ADSs and warrants to purchase 0.5 million ADSs at $13.55. The company had previously filed to raise $65 million by offering 5 million ADSs when its share price was $13.06. At its current price, Benitec Biopharma will raise 61% less proceeds than previously anticipated. The company's proposed market cap fell 26% to $104 million.

Each ADS will now include 0.28 warrants to purchase one ADS at the offer price. Benitec replaced sole bookrunner BMO Capital Markets with former lead manager Maxim Capital.

Benitec Biopharma was founded in 1995 and plans to list on the Nasdaq under the symbol BNTC. IPO timing has not been disclosed.

The article Microcap biotech Benitec Biopharma revives US IPO with 61% lower deal size and warrants originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BNTC

Other Topics

IPOs